Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Mol Aspects Med. 2015 May 27;45:67–73. doi: 10.1016/j.mam.2015.05.004

Table 2.

3rd generation EGFR TKIs in development

T790M Specific EGFRm TKI Current Clinical Status Comments
Rociletinib Phase I and II, III soon Breakthrough Therapy designation
AZD 9291 Phase II and III Breakthrough Therapy designation
EGF 816 Phase I/II
Astellas 8273 Phase I/II
AZD 3759 Phase I
HM 61713 Phase I